Guidi Lorenzo, Cascone Maria Grazia, Rosellini Elisabetta
Department of Civil and Industrial Engineering, University of Pisa, Largo Lucio Lazzarino 1, 56122, Pisa, Italy.
Heliyon. 2024 Feb 18;10(5):e26616. doi: 10.1016/j.heliyon.2024.e26616. eCollection 2024 Mar 15.
A multitude of sight-threatening retinal diseases, affecting hundreds of millions around the globe, lack effective pharmacological treatments due to ocular barriers and common drug delivery limitations. Polymeric nanoparticles (PNPs) are versatile drug carriers with sustained drug release profiles and tunable physicochemical properties which have been explored for ocular drug delivery to both anterior and posterior ocular tissues. PNPs can incorporate a wide range of drugs and overcome the challenges of conventional retinal drug delivery. Moreover, PNPs can be engineered to respond to specific stimuli such as ultraviolet, visible, or near-infrared light, and allow precise spatiotemporal control of the drug release, enabling tailored treatment regimens and reducing the number of required administrations. The objective of this study is to emphasize the therapeutic potential of light-triggered drug-loaded polymeric nanoparticles to treat retinal diseases through an exploration of ocular pathologies, challenges in drug delivery, current production methodologies and recent applications. Despite challenges, light-responsive PNPs hold the promise of substantially enhancing the treatment landscape for ocular diseases, aiming for an improved quality of life for patients.
全球数以亿计的人受多种威胁视力的视网膜疾病影响,由于眼部屏障和常见的药物递送限制,这些疾病缺乏有效的药物治疗方法。聚合物纳米颗粒(PNPs)是多功能药物载体,具有持续的药物释放特性和可调节的物理化学性质,已被用于眼部药物递送至眼前部和后部组织。PNPs可以包载多种药物,并克服传统视网膜药物递送的挑战。此外,PNPs可以设计成响应特定刺激,如紫外线、可见光或近红外光,并实现药物释放的精确时空控制,从而实现定制化治疗方案并减少所需给药次数。本研究的目的是通过探索眼部病理学、药物递送挑战、当前生产方法和近期应用,强调光触发载药聚合物纳米颗粒治疗视网膜疾病的治疗潜力。尽管存在挑战,但光响应性PNPs有望显著改善眼部疾病的治疗前景,旨在提高患者的生活质量。